RecruitingNot applicableNCT05586243

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

Studying Gaucher disease type 3

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: University of Minnesota
Principal Investigator: Reena Kartha, PhD
Intervention: No intervention(other)
Enrollment: 5 enrolled
Eligibility: 18-80 years · All sexes
Timeline: 2023 – 2026

Study locations (1)

University of Minnesota, Minneapolis, Minnesota, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05586243 on ClinicalTrials.gov

Other trials for Gaucher disease type 3

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGNANCT07285369
High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)
Agyany Pharma LTD
ENROLLING BY INVITATIONNANCT06627543
Effect of Enzyme Replacement Therapy on Cardiac Function in Children With Gaucher Disease Type 3
Noha Osman
RECRUITINGNANCT06162338
A Study of the Safety and Preliminary Efficacy of LY-M001 Injection in the Treatment of Adult Patients with Gaucher Disease Type I
He Huang
ACTIVE NOT RECRUITINGPHASE3NCT05222906
Study to Evaluate the Efficacy and Safety of Venglustat in Adult and Pediatric Patients With Gaucher Disease Type 3
Sanofi
RECRUITINGNANCT03240653
Gaucherite - A Study to Stratify Gaucher Disease
Cambridge University Hospitals NHS Foundation Trust

See all trials for Gaucher disease type 3 →

← Back to all trials